NVO Stock Recent News
NVO LATEST HEADLINES
VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to provide a video update on the Company's highly prospective Belltopper Gold Project (“Belltopper”), following the Company's recent announcement titled “Belltopper Mineralisation Modelling Defines Prospectivity” released to the ASX on 25 September 2024 (“Belltopper Announcement”).
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.
Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result.
The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.
Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.
Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S NVO, is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company's diabetes and weight-loss drugs, including Ozempic and Wegovy.
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bagsværd, Denmark, 23 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
The latest news from the Danish drug developer was not encouraging. Its experimental weight loss drug produced results, but also a set of side effects.
Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm's latest obesity treatment showed less effectiveness in higher doses.